ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
ETF Series Solutions Trust Range Cancer Therapeutics

ETF Series Solutions Trust Range Cancer Therapeutics (CNCR)

11,75
-0,2332
(-1,95%)
Fermé 14 Janvier 10:00PM
11,75
0,00
(0,00%)
Après les heures de négociation: 10:30PM

Votre Hub pour des idées et discussions en direct en temps réel

Statistiques et détails clés

Dernier
11,75
Prix Achat
8,73
Prix Vente
14,55
Volume échangé
3 442
11,53 Fourchette du Jour 11,98
11,69 Plage de 52 semaines 18,00
Cap du marché
Clôture Veille
11,9832
Ouverture
11,86
Dernière Transaction
1
@
11.75
Dernière heure de transaction
Volume financier
US$ 40 222
VWAP
11,6858
Volume moyen (3 m)
3 343
Actions en circulation
881 000
Rendement du Dividende
-
Ratio Cours sur Bénéfices
3,86
Bénéfice par action (BPA)
3,03
Chiffre d'affairess
11k
Bénéfice net
2,67M

À propos de ETF Series Solutions Trust Range Cancer Therapeutics

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic f... The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the funds index provider, as having a high strategic focus on the development of drugs that harness the bodys own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified. Show more

Secteur
Mgmt Invt Offices, Open-end
Industrie
Mgmt Invt Offices, Open-end
Siège social
Milwaukee, Wisconsin, USA
Fondé
-
ETF Series Solutions Trust Range Cancer Therapeutics est coté dans le secteur Mgmt Invt Offices, Open-end de la NASDAQ avec le ticker CNCR. Le dernier cours de clôture d'ETF Series Solutions Tru... était de US$11,98. Au cours de la dernière année, les actions de ETF Series Solutions Tru... ont été négociées dans une fourchette de prix de US$ 11,69 à US$ 18,00.

ETF Series Solutions Tru... compte actuellement 881 000 actions en circulation. La capitalisation boursière d'ETF Series Solutions Tru... est de US$10,56 million. ETF Series Solutions Tru... a un ratio cours/bénéfice (ratio PE) de 3.86.

CNCR Dernières nouvelles

EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION

EXCHANGE TRADED CONCEPTS, LLC., ANNOUNCES COMPLETION OF FUND REORGANIZATION PR Newswire OKLAHOMA CITY, Oct. 23, 2023 OKLAHOMA CITY, Oct. 23, 2023 /PRNewswire/ -- Exchange Traded Concepts, LLC...

Loncar China BioPharma ETF (CHNA) Launches on Nasdaq

CHNA offers diversified exposure to leading companies in China’s burgeoning BioPharma industry Today, the Loncar China BioPharma ETF (Nasdaq: CHNA) begins trading on the Nasdaq in the...

Loncar Cancer Immunotherapy ETF (CNCR) Surpasses $50 Million in Assets Under Management

CNCR offers diversified exposure to 30 leading companies with immunotherapy focus The Loncar Cancer Immunotherapy ETF (Nasdaq: CNCR) recently surpassed $50 million in assets under...

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Three Biotechnology Companies Added to the Index Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy...

Loncar Cancer Immunotherapy Index Announces Merger Replacements

Gilead and NewLink Added to the Only Index that Tracks Cancer Immunotherapy Loncar Investments, LLC today announced two new additions to the Loncar Cancer Immunotherapy Index, a group of...

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Three Biotechnology Companies Added to the Index Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy...

Cancer Immunotherapy ETF (Nasdaq: CNCR) to Ring the Nasdaq Stock Market Opening Bell

ADVISORY, Oct. 28, 2016 (GLOBE NEWSWIRE) -- What: Exchange Traded Concepts, Loncar Investments, and Cancer Research Institute will visit the Nasdaq MarketSite in Times Square to...

Cancer Immunotherapy ETF Celebrates One-Year Anniversary

Cancer immunotherapy companies are beneficially disrupting status quo cancer treatments by deploying body’s own immune system to fight disease ETF offers diversified exposure to both...

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Two New Immunotherapy Companies Added to the Index Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy...

Loncar Cancer Immunotherapy Index Conducts Semi-Annual Rebalance

Loncar Investments, LLC today announced the result of the semi-annual rebalance and reconstitution of the Loncar Cancer Immunotherapy Index, a group of the top 30 companies developing...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
1-1.365-10.407929851313.11513.311.69273112.71135651SP
4-1.13-8.7732919254712.8813.311.69401412.41978344SP
12-3.61-23.502604166715.3615.9411.69334313.64819958SP
26-3.35-22.185430463615.116.2711.69360514.42219014SP
52-2.27-16.191155492214.021811.691373515.66464257SP
156-10.08-46.174988547921.8321.839.22897615.20124352SP
260-12.45-51.446280991724.235.8189.22923320.16906804SP
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées